Vanzacaftor is a small-molecule compound designed to correct the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. It is used in combination with other CFTR modulators to enhance CFTR quantity and activity at the cell surface.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 2374124-49-7
Bexotegras
pharmaceutical raw material
Probenecid sodium
pharmaceutical raw material
Retatrutide
pharmaceutical raw material
Ambroxol hydrochloride
pharmaceutical raw material
(14S)-8-[3-(2-dispiro[2.0.24.13]heptan-7-ylethoxy)pyrazol-1-yl]-12,12-dimethyl-2,2-dioxo-2lambda6-thia-3,9,11,18,23-pentazatetracyclo[17.3.1.111,14.05,10]tetracosa-1(22),5(10),6,8,19(23),20-hexaen-4-one
VCSUIBJKYCVWNF-NRFANRHFSA-N
CC1(C[C@@H]2CCCNC3=NC(=CC=C3)S(=O)(=O)NC(=O)C4=C(N1C2)N=C(C=C4)N5C=CC(=N5)OCCC6C7(C68CC8)CC7)C